Switch to:
More From Other Websites
Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and... Dec 15 2014
Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and... Dec 15 2014
EXELIXIS, INC. Files SEC form 8-K, Other Events Dec 05 2014
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib Dec 02 2014
Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study Dec 01 2014
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With... Dec 01 2014
Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With... Dec 01 2014
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 Nov 25 2014
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888... Nov 16 2014
EXELIXIS, INC. Financials Nov 14 2014
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 Nov 11 2014
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic... Nov 06 2014
Exelixis tops 3Q profit forecasts Nov 04 2014
Exelixis tops 3Q profit forecasts Nov 04 2014
Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Nov 04 2014
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 04 2014
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in... Nov 04 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK